These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38041002)

  • 1. Correction: Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
    Yu F; Li L; Zhang M; Sun S
    BMC Cancer; 2023 Dec; 23(1):1176. PubMed ID: 38041002
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
    Yu F; Li L; Zhang M; Sun S
    BMC Cancer; 2023 Oct; 23(1):948. PubMed ID: 37803297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
    Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
    Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy.
    Bao Y; Oguz G; Lee WC; Lee PL; Ghosh K; Li J; Wang P; Lobie PE; Ehmsen S; Ditzel HJ; Wong A; Tan EY; Lee SC; Yu Q
    Nat Commun; 2020 Nov; 11(1):5878. PubMed ID: 33208750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
    Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
    Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers.
    Yang CC; LaBaff A; Wei Y; Nie L; Xia W; Huo L; Yamaguchi H; Hsu YH; Hsu JL; Liu D; Lang J; Du Y; Lien HC; Li LY; Deng R; Chan LC; Yao J; Kleer CG; Hortobagyi GN; Hung MC
    Am J Transl Res; 2015; 7(6):1009-20. PubMed ID: 26279746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
    Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
    Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast Cancer.
    Jang SH; Lee JE; Oh MH; Lee JH; Cho HD; Kim KJ; Kim SY; Han SW; Kim HJ; Bae SB; Lee HJ
    J Breast Cancer; 2016 Mar; 19(1):53-60. PubMed ID: 27066096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation.
    Hu C; Wang M; Hu M; Ma S; Yang B; Xiao W; Zhou Q; Zhou M; Li Z
    Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36356296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma.
    Pattanayak B; Garrido-Cano I; Adam-Artigues A; Tormo E; Pineda B; Cabello P; Alonso E; Bermejo B; Hernando C; Martínez MT; Rovira A; Albanell J; Rojo F; Burgués O; Cejalvo JM; Lluch A; Eroles P
    Front Oncol; 2020; 10():1661. PubMed ID: 33014831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer.
    Donnelly SM; Paplomata E; Peake BM; Sanabria E; Chen Z; Nahta R
    Curr Med Chem; 2014; 21(4):501-10. PubMed ID: 24251561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility.
    Brandt B; Kemming D; Packeisen J; Simon R; Helms M; Feldmann U; Matuschek A; Kersting C; Hinrichs B; Bidart JM; Bellet D; Bartkowiak K; Dankbar N; Dittmar T; Sauter G; Boecker W; Buerger H
    Endocr Relat Cancer; 2005 Dec; 12(4):823-37. PubMed ID: 16322324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High EZH2 expression in ductal carcinoma in situ diagnosed on breast core needle biopsy is an independent predictive factor for upgrade on surgical excision.
    Genco IS; Ozgultekin B; Hosseini H; Hackman K; Ferreira L; Santagada E; Wahl S; Hajiyeva S
    Pathol Res Pract; 2020 Dec; 216(12):153283. PubMed ID: 33197837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of clinicopathologic characteristics and outcomes with
    Boostani F; Dolatkhah R; Fakhrjou A; Farassati F; Sanaat Z
    Onco Targets Ther; 2018; 11():449-457. PubMed ID: 29403289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells.
    Patki M; Salazar Md; Trumbly R; Ratnam M
    Biochem Biophys Res Commun; 2015 Feb; 457(3):404-11. PubMed ID: 25582774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling.
    Hu C; Liu Y; Teng M; Jiao K; Zhen J; Wu M; Li Z
    Cell Biol Toxicol; 2019 Oct; 35(5):445-456. PubMed ID: 30941654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plumbagin Suppresses the Invasion of HER2-Overexpressing Breast Cancer Cells through Inhibition of IKKα-Mediated NF-κB Activation.
    Kawiak A; Domachowska A
    PLoS One; 2016; 11(10):e0164064. PubMed ID: 27727280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis.
    Li Z; Wang D; Chen X; Wang W; Wang P; Hou P; Li M; Chu S; Qiao S; Zheng J; Bai J
    Cell Death Dis; 2021 Nov; 12(11):1080. PubMed ID: 34775498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression.
    Gonzalez ME; Naimo GD; Anwar T; Paolì A; Tekula SR; Kim S; Medhora N; Leflein SA; Itkin J; Trievel R; Kidwell KM; Chen YC; Mauro L; Yoon E; Andò S; Kleer CG
    iScience; 2022 Aug; 25(8):104827. PubMed ID: 35992062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.